A Phase 3 interventional study of Daratumumab IV and Lenalidomide in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 206 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.
Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 5th largest by enrollment, is one of 7 that started in 2015, is one of 24 in phase 3, and was the 7th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 84 · Phase 3 25 · Phase 4 4
First in 2008; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 737 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 132 interventional studies. Of the 55 that completed or were terminated, 28 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 7th largest by enrollment of the 100 interventional ones that give a count, is one of 4 that started in 2015, is one of 35 in phase 3, and was the 57th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
19 of the studies testing daratumumab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
| NCT04991103University of Alabama at BirminghamMinimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | 2027-01-01 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 132 studies testing daratumumab in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT).
This is a Phase 3, randomized (study drug assigned by chance), open-label (participants and researchers are aware about the treatment, participants are receiving), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), parallel-group (each group of participants will be treated at the same time), and multicenter (when more than one hospital or medical school team work on a medical research study) study in participants with newly diagnosed multiple myeloma and who are not candidates for high dose chemotherapy and ASCT. All the eligible participants will be randomly assigned to receive either lenalidomide and dexamethasone (Rd) (Arm A) or daratumumab in combination with lenalidomide and dexamethasone (DRd) (Arm B). Daratumumab (16 milligram per kilogram [mg/kg]) will be administered weekly for first 8 weeks (Cycles 1 to 2) of treatment and then every other week for 16 weeks (Cycles 3 to 6), then every 4 weeks (from Cycle 7 and beyond) until progression of disease or unacceptable toxicity. Lenalidomide will be administered at a dose of 25 mg orally on Days 1 through 21 of each 28-day cycle, and dexamethasone will be administered at a dose of 40 mg once a week for both treatment arms. Participants in both treatment arms will continue lenalidomide and dexamethasone until disease progression or unacceptable toxicity. All participants randomized to Treatment Arm B (DRd) in this study initially received daratumumab IV formulation; however, following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Participants in Arm A who have sponsor-confirmed disease progression may have the option to receive daratumumab provided by the sponsor (in any subsequent line of therapy) in the Follow-up phase. The study consists of 3 phases: Screening Phase (within 21 days prior to the first dose administration on Day 1), Treatment Phase (Day 1 up to discontinuation of all study treatment), and Follow-up Phase (from discontinuation of all study treatment up to death, lost to follow up, consent withdrawal, or study end, whichever occurs first). The maximum duration of study will be 7 years after last participant is randomized. Efficacy will primarily be evaluated by PFS. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
Drug: Daratumumab IV · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
Drug: Lenalidomide · Drug: Dexamethasone · Drug: Daratumumab SC
Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
Also known as: JNJ-54767414
Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
Dexamethasone 40 mg orally or intravenously once in a week.
Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
Also known as: JNJ-54767414
Progression-free Survival (PFS)
PFS was defined as time from date of randomization to either progressive disease (PD) or death, whichever occurred first based on computerized algorithm as per IMWG criteria. PD was defined as an increase of 25 percent (%) from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \[\>=\] 0.5 gram per deciliter \[g/dL\] and \>=200 milligram \[mg\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\]10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that could be attributed solely to Plasma cell (PC) proliferative disorder.
Time frame: From randomization (Day -3) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)
Percentage of Participants With Complete Response (CR) or Better
Percentage of participants with a CR or better (CR or stringent complete response \[sCR\]) based on computerized algorithm as per IMWG criteria was reported. CR was defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\<) 5 percent (%) PCs in bone marrow. In participants with only measurable disease by serum FLC levels a normal serum FLC ratio was required. sCR was defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescence, 2-4 color flow cytometry (FC).
Time frame: From randomization (Day -3) up to 6.6 years
Percentage of Participants With Very Good Partial Response (VGPR) or Better
VGPR or better rate was defined as the percentage of participants who achieved VGPR or better (VGPR, CR or sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level less than (\<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC.
Time frame: From randomization (Day -3) up to 6.6 years
Percentage of Participants With Negative Minimal Residual Disease (MRD)
MRD negativity rate is defined as the percentage of participants who had negative MRD at any time point after the date of randomization and prior to subsequent antimyeloma therapy. MRD was assessed in participants who achieved CR or better.
Time frame: From randomization (Day -3) up to 6.6 years
Percentage of Participants With Stringent Complete Response (sCR)
sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by IHC, immunofluorescence or 2- to 4-color FC. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; \<5% PCs in bone marrow.
Time frame: From randomization (Day -3) up to 6.6 years
Overall Response Rate (ORR)
ORR was the percentage of participants who achieved partial response (PR) or better (PR, VGPR, CR or sCR) based on computerized algorithm as per IMWG criteria. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours. If serum and urine M-protein were not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels was required in place of the M-protein criteria. If present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required. VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours. CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC.
Time frame: From randomization (Day -3) up to 6.6 years
Overall Survival (OS)
OS was measured from the date of randomization to the date of the death. Median OS was estimated by using the Kaplan-Meier method.
Time frame: From randomization (Day -3) up to 8.7 years
Time to Disease Progression (TTP)
TTP was defined as the time from the date of randomization to date of first documented evidence of PD or death due to PD, whichever occurred first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.
Time frame: From randomization (Day -3) up to 6.6 years
Time to Response
Time to first response, time to VGPR or better, time to CR or better and time to best response was reported for this endpoint. Time to response: time from date of randomization to first efficacy evaluation that met criteria for PR/better as their best response (PR, CR, or better) based on IMWG criteria. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours. If serum and urine M-protein were not measurable, a decrease of \>=50% in difference between involved and uninvolved FLC levels was required in place of M-protein criteria. Based on computerized algorithm, according to IMWG response criteria, VGPR or better: proportion of participants with a response of VGPR or better (i.e., VGPR, CR or sCR), CR or better: proportion of participants with a response of CR or better (i.e., CR or sCR).
Time frame: From randomization (Day -3) up to 6.6 years
Duration of Response (DoR)
DoR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression per IMWG response criteria, or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.
Time frame: From randomization (Day -3) up to 6.6 years
Time to Subsequent Anti-myeloma Treatment
Time to subsequent anti-myeloma treatment was defined as the time from randomization to the start of subsequent anti-myeloma treatment. Kaplan-Meier method was used for the analysis.
Time frame: From randomization (Day -3) up to 8.7 years
Progression-free Survival on Next Line of Therapy (PFS2)
PFS2 was defined as the time from randomization to progression on next line of therapy or death, whichever comes first. Disease progression on next line of treatment was based on investigator judgment.
Time frame: From randomization (Day -3) up to 6.6 years
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Global Health Status Score
EORTC QLQ-C30 was 30 items self-reporting questionnaire, with 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire included 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related QoL. Scores were transformed to 0 to 100 scale, with higher scores represented better GHS and functioning, and more symptoms. Negative change from baseline values showed deterioration in quality of life or functioning and reduction in symptom and positive values indicated improvement and worsening of symptoms.
Time frame: Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS)
EQ-5D-5L was a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale was designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
Time frame: Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score
EQ-5D-5L was standardized, participant-reported questionnaire to assess health-related quality of life. EQ-5D-5L included 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L VAS. EQ-5D-5L descriptive system provided a profile of participant's health state 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflected increasing levels of difficulty. Participants indicated their health state by selecting the most appropriate level in each of the 5D. Responses to the 5D scores were combined and converted into single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of individual (but allows for values less than 0 by United kingdom scoring algorithm). Higher score indicated better health state.
Time frame: Baseline (Day -24) and Day 1 of Cycles 3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54, 60 and 66 (each Cycle of 28 days)
Sub-group Analysis: Progression-free Survival (PFS)
PFS for participants with cytogenic high risk was reported. PFS was time from date of randomization to either PD or death, whichever occurred first based on computerized algorithm as per IMWG criteria. PD: an increase of 25% from lowest response value in one of following: serum and urine M-component (absolute increase must be \>=0.5 g/dL and \>=200 mg/24h respectively); Only in participants without measurable serum and urine M-protein levels, difference between involved and uninvolved FLC levels (absolute \>10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that could be attributed solely to PC proliferative disorder. High risk was defined as positive for any of del17p, t(14;16) or t(4;14) by (corrected serum calcium \>11.5 mg/dL) Fluorescence In Situ Hybridization (FISH)/Karyotype.
Time frame: From randomization (Day -3) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 6.6 years).
Sub-group Analysis: Overall Response Rate (ORR)
ORR for participants with cytogenic high risk was reported. ORR: percentage of participants who achieved PR/better per IMWG criteria. PR: \>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90% or \<200mg/24h. If serum/urine M-protein were not measurable, decrease of \>=50% in difference between involved and uninvolved FLC levels was required in place of M-protein criteria. If present at baseline, \>=50% reduction in size of soft tissue plasmacytomas was required. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum and urine M-protein \<100mg/24h. CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, \<5% PCs in bone marrow; sCR: CR in addition to normal FLC ratio, absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC. High risk: positive for any of del17p, t(14;16) or t(4;14) by FISH/Karyotype.
Time frame: From randomization (Day -3) up to 6.6 years
| Milestone | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Started | 369 | 368 |
| Treated | 365 | 364 |
| Completed | 0 | 0 |
| Not completed | 369 | 368 |
| Withdrew: Lost to follow-up | 9 | 6 |
| Withdrew: Death | 218 | 175 |
| Withdrew: Withdrawal by subject | 20 | 15 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: End of data collection | 122 | 170 |
| Withdrew: Site closure | 0 | 1 |
PFS was defined as time from date of randomization to either progressive disease (PD) or death, whichever occurred first based on computerized algorithm as per IMWG criteria. PD was defined as an increase of 25 percent (%) from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \[\>=\] 0.5 gram per deciliter \[g/dL\] and \>=200 milligram \[mg\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\]10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that could be attributed solely to Plasma cell (PC) proliferative disorder.
| Months | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Progression-free Survival (PFS) | 31.87 (28.94 to NA) | NA (NA to NA) |
Percentage of participants with a CR or better (CR or stringent complete response \[sCR\]) based on computerized algorithm as per IMWG criteria was reported. CR was defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\<) 5 percent (%) PCs in bone marrow. In participants with only measurable disease by serum FLC levels a normal serum FLC ratio was required. sCR was defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescence, 2-4 color flow cytometry (FC).
| Percentage of participants | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Better | 30.1 (25.4 to 35.0) | 51.1 (45.9 to 56.3) |
VGPR or better rate was defined as the percentage of participants who achieved VGPR or better (VGPR, CR or sCR) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level less than (\<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC.
| Percentage of participants | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Percentage of Participants With Very Good Partial Response (VGPR) or Better | 56.9 (51.7 to 62.0) | 81.5 (77.2 to 85.4) |
MRD negativity rate is defined as the percentage of participants who had negative MRD at any time point after the date of randomization and prior to subsequent antimyeloma therapy. MRD was assessed in participants who achieved CR or better.
| Percentage of participants | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Percentage of Participants With Negative Minimal Residual Disease (MRD) | 11.1 (8.1 to 14.8) | 32.1 (27.3 to 37.1) |
sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by IHC, immunofluorescence or 2- to 4-color FC. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; \<5% PCs in bone marrow.
| Percentage of participants | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Percentage of Participants With Stringent Complete Response (sCR) | 15.7 (12.2 to 19.8) | 35.6 (30.7 to 40.7) |
ORR was the percentage of participants who achieved partial response (PR) or better (PR, VGPR, CR or sCR) based on computerized algorithm as per IMWG criteria. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours. If serum and urine M-protein were not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels was required in place of the M-protein criteria. If present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required. VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours. CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% PCs in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC.
| Percentage of participants | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Overall Response Rate (ORR) | 81.6 (77.2 to 85.4) | 92.9 (89.8 to 95.3) |
OS was measured from the date of randomization to the date of the death. Median OS was estimated by using the Kaplan-Meier method.
| Months | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Overall Survival (OS) | 64.07 (55.98 to 70.80) | 90.25 (80.76 to NA) |
TTP was defined as the time from the date of randomization to date of first documented evidence of PD or death due to PD, whichever occurred first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.
| Months | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Time to Disease Progression (TTP) | 40.87 (35.81 to 48.79) | NA (NA to NA) |
Time to first response, time to VGPR or better, time to CR or better and time to best response was reported for this endpoint. Time to response: time from date of randomization to first efficacy evaluation that met criteria for PR/better as their best response (PR, CR, or better) based on IMWG criteria. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours. If serum and urine M-protein were not measurable, a decrease of \>=50% in difference between involved and uninvolved FLC levels was required in place of M-protein criteria. Based on computerized algorithm, according to IMWG response criteria, VGPR or better: proportion of participants with a response of VGPR or better (i.e., VGPR, CR or sCR), CR or better: proportion of participants with a response of CR or better (i.e., CR or sCR).
| Months | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Time to first response | 1.05 (0.3 to 22.3) | 1.05 (0.2 to 12.1) |
| Time to VGPR or better | 4.70 (0.9 to 43.3) | 3.01 (0.9 to 60.9) |
| Time to CR or better | 13.17 (2.8 to 54.6) | 10.66 (1.0 to 46.7) |
| Time to best response | 6.31 (0.9 to 55.2) | 9.97 (0.9 to 60.9) |
DoR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression per IMWG response criteria, or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.
| Months | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Duration of Response (DoR) | 43.7 (36.8 to 52.6) | NA (NA to NA) |
Time to subsequent anti-myeloma treatment was defined as the time from randomization to the start of subsequent anti-myeloma treatment. Kaplan-Meier method was used for the analysis.
| Months | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Time to Subsequent Anti-myeloma Treatment | 42.4 (33.5 to 50.6) | NA (84.1 to NA) |
PFS2 was defined as the time from randomization to progression on next line of therapy or death, whichever comes first. Disease progression on next line of treatment was based on investigator judgment.
| Months | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Progression-free Survival on Next Line of Therapy (PFS2) | 48.89 (44.09 to 56.57) | 73.72 (73.72 to NA) |
EORTC QLQ-C30 was 30 items self-reporting questionnaire, with 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire included 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related QoL. Scores were transformed to 0 to 100 scale, with higher scores represented better GHS and functioning, and more symptoms. Negative change from baseline values showed deterioration in quality of life or functioning and reduction in symptom and positive values indicated improvement and worsening of symptoms.
| Score on scale | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Cycle 3 Day 1 | 1.4 (-0.7 to 3.5) | 3.8 (1.7 to 5.8) |
| Cycle 6 Day 1 | 4.8 (2.6 to 7) | 6.3 (4.3 to 8.4) |
| Cycle 9 Day 1 | 5.7 (3.4 to 8) | 7.5 (5.4 to 9.7) |
| Cycle 12 Day 1 | 4.5 (2.2 to 6.8) | 7.8 (5.6 to 9.9) |
| Cycle 18 Day 1 | 4.7 (2.2 to 7.2) | 6.4 (4.1 to 8.6) |
| Cycle 24 Day 1 | 4.7 (2.1 to 7.4) | 6.3 (4.1 to 8.6) |
| Cycle 30 Day 1 | 4.5 (1.7 to 7.3) | 5.5 (3.1 to 7.9) |
| Cycle 36 Day 1 | 5 (2 to 8) | 7.7 (5.3 to 10.1) |
| Cycle 42 Day 1 | 3.8 (0.6 to 7) | 5.6 (3.1 to 8.1) |
| Cycle 48 Day 1 | 3.4 (-0.1 to 6.9) | 4.2 (1.6 to 6.7) |
| Cycle 54 Day 1 | 6.1 (2.2 to 9.9) | 4.8 (2 to 7.5) |
| Cycle 60 Day 1 | 4.9 (0.4 to 9.4) | 4.1 (1.1 to 7.1) |
| Cycle 66 Day 1 | 7.1 (1.3 to 12.8) | 7.7 (4.2 to 11.2) |
EQ-5D-5L was a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale was designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
| Score on scale | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Cycle 3 Day 1 | 2.1 (0.3 to 4) | 4.2 (2.3 to 6) |
| Cycle 6 Day 1 | 4.8 (2.8 to 6.8) | 7.6 (5.8 to 9.5) |
| Cycle 9 Day 1 | 7 (5 to 9.1) | 9.6 (7.7 to 11.5) |
| Cycle 12 Day 1 | 3.6 (1.6 to 5.7) | 9.4 (7.4 to 11.3) |
| Cycle 18 Day 1 | 5.4 (3.2 to 7.6) | 7.4 (5.4 to 9.4) |
| Cycle 24 Day 1 | 4.3 (2 to 6.7) | 7 (5 to 9) |
| Cycle 30 Day 1 | 4.6 (2.1 to 7) | 6.9 (4.8 to 9.1) |
| Cycle 36 Day 1 | 4.9 (2.3 to 7.5) | 8.1 (6 to 10.2) |
| Cycle 42 Day 1 | 4.6 (1.8 to 7.3) | 5.6 (3.4 to 7.8) |
| Cycle 48 Day 1 | 5.5 (2.4 to 8.5) | 6.7 (4.5 to 9) |
| Cycle 54 Day 1 | 3.4 (0.1 to 6.7) | 5.8 (3.4 to 8.2) |
| Cycle 60 Day 1 | 5.8 (1.9 to 9.6) | 5.2 (2.6 to 7.8) |
| Cycle 66 Day 1 | 6.9 (2 to 11.8) | 5.6 (2.5 to 8.7) |
EQ-5D-5L was standardized, participant-reported questionnaire to assess health-related quality of life. EQ-5D-5L included 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L VAS. EQ-5D-5L descriptive system provided a profile of participant's health state 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflected increasing levels of difficulty. Participants indicated their health state by selecting the most appropriate level in each of the 5D. Responses to the 5D scores were combined and converted into single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of individual (but allows for values less than 0 by United kingdom scoring algorithm). Higher score indicated better health state.
| Score on scale | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Cycle 3 Day 1 | 0.081 (0.058 to 0.103) | 0.097 (0.074 to 0.119) |
| Cycle 6 Day 1 | 0.111 (0.087 to 0.135) | 0.13 (0.107 to 0.152) |
| Cycle 9 Day 1 | 0.113 (0.088 to 0.138) | 0.124 (0.101 to 0.147) |
| Cycle 12 Day 1 | 0.103 (0.078 to 0.128) | 0.132 (0.108 to 0.155) |
| Cycle 18 Day 1 | 0.089 (0.062 to 0.116) | 0.116 (0.092 to 0.14) |
| Cycle 24 Day 1 | 0.088 (0.059 to 0.116) | 0.121 (0.096 to 0.145) |
| Cycle 30 Day 1 | 0.088 (0.058 to 0.118) | 0.102 (0.076 to 0.127) |
| Cycle 36 Day 1 | 0.099 (0.067 to 0.131) | 0.109 (0.083 to 0.135) |
| Cycle 42 Day 1 | 0.062 (0.028 to 0.096) | 0.113 (0.086 to 0.14) |
| Cycle 48 Day 1 | 0.075 (0.038 to 0.112) | 0.082 (0.055 to 0.11) |
| Cycle 54 Day 1 | 0.05 (0.01 to 0.091) | 0.087 (0.058 to 0.116) |
| Cycle 60 Day 1 | 0.068 (0.02 to 0.115) | 0.079 (0.047 to 0.111) |
| Cycle 66 Day 1 | 0.041 (-0.019 to 0.102) | 0.111 (0.073 to 0.148) |
PFS for participants with cytogenic high risk was reported. PFS was time from date of randomization to either PD or death, whichever occurred first based on computerized algorithm as per IMWG criteria. PD: an increase of 25% from lowest response value in one of following: serum and urine M-component (absolute increase must be \>=0.5 g/dL and \>=200 mg/24h respectively); Only in participants without measurable serum and urine M-protein levels, difference between involved and uninvolved FLC levels (absolute \>10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that could be attributed solely to PC proliferative disorder. High risk was defined as positive for any of del17p, t(14;16) or t(4;14) by (corrected serum calcium \>11.5 mg/dL) Fluorescence In Situ Hybridization (FISH)/Karyotype.
| Months | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Sub-group Analysis: Progression-free Survival (PFS) | 29.6 (15.6 to 34.5) | 45.3 (18.4 to 61.9) |
ORR for participants with cytogenic high risk was reported. ORR: percentage of participants who achieved PR/better per IMWG criteria. PR: \>=50% reduction of serum M-protein, reduction in 24h urinary M-protein by \>=90% or \<200mg/24h. If serum/urine M-protein were not measurable, decrease of \>=50% in difference between involved and uninvolved FLC levels was required in place of M-protein criteria. If present at baseline, \>=50% reduction in size of soft tissue plasmacytomas was required. VGPR: serum/urine M-component detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum and urine M-protein \<100mg/24h. CR: negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, \<5% PCs in bone marrow; sCR: CR in addition to normal FLC ratio, absence of clonal cells in bone marrow by IHC, immunofluorescence, 2-4 color FC. High risk: positive for any of del17p, t(14;16) or t(4;14) by FISH/Karyotype.
| Percentage of participants | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| Sub-group Analysis: Overall Response Rate (ORR) | 75.0 | 91.7 |
Collected over All-cause mortality: From randomization (Day -3) up to 8.7 years; Serious and Other AEs: From start of treatment (Day 1) up to 6.6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide + Dexamethasone (Rd) | 259/369 (70.2%) | 262/365 (71.8%) | 358/365 (98.1%) |
| Daratumumab + Lenalidomide + Dexamethasone (DRd) | 287/368 (78%) | 289/364 (79.4%) | 362/364 (99.5%) |
| Event | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| PneumoniaInfections and infestations | 39/365 | 68/364 |
| PyrexiaGeneral disorders | 12/365 | 20/364 |
| InfluenzaInfections and infestations | 8/365 | 17/364 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 14/365 | 16/364 |
| BronchitisInfections and infestations | 6/365 | 15/364 |
| Atrial FibrillationCardiac disorders | 15/365 | 10/364 |
| Acute Kidney InjuryRenal and urinary disorders | 15/365 | 14/364 |
| Back PainMusculoskeletal and connective tissue disorders | 9/365 | 14/364 |
| Urinary Tract InfectionInfections and infestations | 7/365 | 12/364 |
| AnaemiaBlood and lymphatic system disorders | 12/365 | 6/364 |
| Event | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 186/365 | 237/364 |
| NeutropeniaBlood and lymphatic system disorders | 167/365 | 224/364 |
| FatigueGeneral disorders | 114/365 | 163/364 |
| ConstipationGastrointestinal disorders | 136/365 | 156/364 |
| Oedema PeripheralGeneral disorders | 117/365 | 156/364 |
| AnaemiaBlood and lymphatic system disorders | 148/365 | 154/364 |
| Back PainMusculoskeletal and connective tissue disorders | 107/365 | 147/364 |
| AstheniaGeneral disorders | 99/365 | 134/364 |
| NauseaGastrointestinal disorders | 87/365 | 133/364 |
| InsomniaPsychiatric disorders | 116/365 | 125/364 |
| Age, Continuous(Years) | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) | Total |
|---|---|---|---|
| Mean | 74.2 ± 5.66 | 74.0 ± 5.44 | 74.1 ± 5.55 |
| Sex: Female, Male(Participants) | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) | Total |
|---|---|---|---|
| Female | 174 | 179 | 353 |
| Male | 195 | 189 | 384 |
| Ethnicity (NIH/OMB)(Participants) | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 11 | 23 |
| Not Hispanic or Latino | 352 | 347 | 699 |
| Unknown or Not Reported | 5 | 10 | 15 |
| Race/Ethnicity, Customized(Participants) | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) | Total |
|---|---|---|---|
| White | 339 | 336 | 675 |
| Black or African American | 16 | 12 | 28 |
| Asian | 2 | 3 | 5 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| Other | 6 | 6 | 12 |
| Unknown | 1 | 2 | 3 |
| Not Reported | 4 | 9 | 13 |
| Region of Enrollment(Participants) | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) | Total |
|---|---|---|---|
| Australia | 18 | 17 | 35 |
| Austria | 11 | 3 | 14 |
| Belgium | 5 | 2 | 7 |
| Canada | 28 | 24 | 52 |
| Denmark | 6 | 10 | 16 |
| France | 155 | 157 | 312 |
| Germany | 16 | 19 | 35 |
| Ireland | 3 | 4 | 7 |
| Israel | 3 | 5 | 8 |
| Italy | 3 | 3 | 6 |
| Netherlands | 1 | 4 | 5 |
| Sweden | 12 | 10 | 22 |
| United Kingdom | 34 | 33 | 67 |
| United States | 74 | 77 | 151 |
| Stage of Disease (ISS)(Participants) | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) | Total |
|---|---|---|---|
| Stage I | 103 | 98 | 201 |
| Stage II | 156 | 163 | 319 |
| Stage III | 110 | 107 | 217 |
| Time from Multiple Myeloma (MM) diagnosis(Months) | Lenalidomide + Dexamethasone (Rd) | Daratumumab + Lenalidomide + Dexamethasone (DRd) | Total |
|---|---|---|---|
| Mean | 1.3 ± 1.4 | 1.4 ± 1.5 | 1.3 ± 1.5 |
Showing the first 100 of 206 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Sep 2018, 43 months.
Results were first posted in Jan 2020, 1 year 3 months after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 43 months is close to that.
Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →